Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy Untreated CNS metastatic disease, leptomeningeal disease, or cord compression Symptomatic or untreated leptomeningeal disease or spinal cord compression Patients with untreated spinal cord metastases are eligible if lesions are asymptomatic Has a history of untreated brain metastasis or history of leptomeningeal disease or spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression; treated brain metastases must have been stable for at least month and require treatment with less than mg/day prednisone equivalent for at least two weeks prior to study drug administration Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression; treated brain metastases are allowed as long as they are stable for at least days post-treatment Symptomatic or untreated brain metastases, leptomeningeal disease, or spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression; if these were treated and clinically stable for weeks, patient can be considered for the trial Has symptomatic or untreated leptomeningeal, brain metastases, or spinal cord compression. Untreated symptomatic spinal cord compressions Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression (patients with controlled central nervous system [CNS] disease, i.e. asymptomatic and currently receiving concurrent intrathecal chemotherapy, are eligible upon discussion with the principal investigator) Symptomatic or untreated CNS metastases or spinal cord compression. Brain metastasis must be stable with verification by imaging . Are symptomatic or have uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation (brain metastases that are stable and asymptomatic, either treated or untreated, will be allowed) Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Symptomatic or untreated leptomeningeal disease, brain metastasis, or spinal cord compression Untreated or active primary brain tumor, central nervous system (CNS) metastases, or spinal cord compression Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression Active or untreated brain metastases or spinal cord compression Symptomatic or untreated spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Symptomatic or untreated spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Patients with symptomatic or untreated leptomeningeal or brain metastasis or spinal cord compression Have known untreated brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease. Untreated symptomatic spinal cord compressions Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Untreated spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression; treated brain metastases must have been stable for at least month Untreated brain metastasis or history of leptomeningeal disease or spinal cord compression. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Untreated symptomatic spinal cord compressions History of, or current metastases in the brain, meninges, or untreated spinal cord compression History of, or current known metastases in the brain or untreated spinal cord compression Symptomatic or untreated leptomeningeal, CNS or brain metastases or spinal cord compression at the time of transition to this study. Untreated spinal cord compression. Symptomatic or untreated leptomeningeal disease or brain metastases or spinal cord compression Untreated or inadequately treated spinal cord compression Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression; treated brain metastases must have been stable for at least month Symptomatic or untreated brain metastases or spinal cord compression or any of these conditions requiring chronic steroids to control symptoms. Diagnosis of primary brain tumor; untreated brain metastasis or history of leptomeningeal disease or spinal cord compression; Untreated brain metastasis or history of leptomeningeal disease or spinal cord compression; Untreated or symptomatic brain metastasis, leptomeningeal disease or spinal cord compression. Subjects who are on a stable dose of corticosteroids for more than month or off corticosteroids for weeks can be enrolled with approval of medical monitor. Subjects are not permitted to receive enzyme-inducing anti-epileptic drugs. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression; patients with treated central nervous system (CNS) metastasis, no longer requiring steroid therapy are potentially eligible; patients with primary glioblastoma multiforme not requiring steroid therapy will be eligible Patients with a current, untreated spinal cord compression